Intervention

Vildagliptin 50 MG

ClinicalTrials.gov intervention label

Clinical trials6

Recruiting0

Common conditions7

Lead sponsors shown4

Clinical trials

6 shown

Empagliflozin Versus Vildagliptin in CAD Patients With T2DMNCT06313008 · 2023-08-10

Vildagliptin Versus Glimepiride in Type 2 Diabetic PatientsNCT06068686 · 2022-10-01

Vildagliptin for Treatment of Antipsychotic-induced DyslipidemiaNCT04761861 · 2021-02-16

The DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder PatientsNCT04410341 · 2020-05-01

Safety and Efficacy of Antidiabetic Drugs in Recently Diagnosed Patients With Type 2 DiabetesNCT04916093 · 2019-12-20

The Study Aims to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safeyt Profile of Test Product Compared to Reference Product Will be Assessed.NCT05329844 · 2014-02-01

Common conditions

Type 2 Diabetes2 Coronary Artery Disease1 Diabetes Mellitus1 Diabetes Mellitus, Type 21 Dyslipidemias1 Major Depressive Disorder1 Schizophrenia1

Leading sponsors

Damanhour University2 Sadat City University2 AET Laboratories Private Limited1 Beni-Suef University1

Trial status mix

COMPLETED4

WITHDRAWN2

Phase mix

NA3

PHASE22

PHASE11

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.